Table 2.
Univariable Cox proportional hazards regression analysis of clinical and CMR characteristics for prediction of adverse pericardial events
| Variable | Hazard ratio (95% CI) | p-value |
|---|---|---|
| Gender | 1.2 (0.31–4.3) | 0.83 |
| Age | 1 (1–1.1) | 0.024 |
| Height | 1 (0.95–1.1) | 0.51 |
| Weight | 1.1 (1–1.1) | 0.031 |
| Hypertension | 1.8 (0.56–5.6) | 0.33 |
| Dyslipidemia | 1.7 (0.45–6.3) | 0.44 |
| Obesity | 2.2 (0.6–8.2) | 0.23 |
| Current or previous smoking | 1.5 (0.45–4.9) | 0.52 |
| Diabetes mellitus | 4 (1–15) | 0.044 |
| Family history of coronary disease | 1.6 (0.48–5.3) | 0.45 |
| Chest pain | 1 (0.3–3.3) | 0.99 |
| Heart failure | 2.5 (0.54–12) | 0.24 |
| Arrhythmias | 3.2 (0.41–26) | 0.27 |
| Leukocytosis | 1.1 (0.34–3.8) | 0.84 |
| CRP | 0.43 (0.13–1.4) | 0.17 |
| Erythrocyte sedimentation rate | 2.6 (0.84–8.2) | 0.097 |
| Fever | 2.2 (0.69–6.8) | 0.18 |
| Troponin | 0.64 (0.14–2.9) | 0.57 |
| Subacute course | 0.98 (0.27–3.6) | 0.98 |
| Respond to non-steroidal anti-inflammatory drugs | 0.35 (0.1–1.2) | 0.092 |
| Pericardial thickness | 1.1 (0.85–1.3) | 0.6 |
| Pericardial effusion | 1.9 (0.6–6.1) | 0.28 |
| Pericardial effusion (thickness) | 1 (1–1.1) | 0.029 |
| Reservoir | 0.92 (0.88–0.97) | 0.0012 |
| Reservoir rate | 0.29 (0.11–0.77) | 0.013 |
| Conduit | 0.85 (0.78–0.94) | 0.00087 |
| Conduit rate | 2.5 (1.1–5.9) | 0.034 |
| Booster | 0.9 (0.81–0.99) | 0.036 |
| Booster rate | 3 (1.3–6.9) | 0.011 |
| LV ejection fraction | 1 (0.94–1.1) | 0.61 |
| LV mass index | 1 (0.98–1) | 0.74 |
| BSA-indexed LV end-diastolic volume | 0.98 (0.96–1) | 0.068 |
| BSA-indexed LV end-systolic volume | 0.96 (0.92–1) | 0.097 |
| BSA-indexed LV stroke volume | 0.95 (0.9–1) | 0.049 |
| BSA-indexed LV mass | 1 (0.96–1) | 0.83 |
| RV ejection fraction | 1 (0.91–1.1) | 0.95 |
| BSA-indexed RV end-diastolic volume | 0.97 (0.94–1) | 0.13 |
| BSA-indexed RV end-systolic volume | 0.97 (0.9–1) | 0.33 |
| BSA-indexed RV stroke volume | 0.94 (0.88–1) | 0.051 |
| LV strain | ||
| Basal radial | 1 (0.96–1.1) | 0.41 |
| Basal circumferential | 0.95 (0.81–1.1) | 0.52 |
| Basal longitudinal | 0.99 (0.83–1.2) | 0.88 |
| Mid radial | 1 (0.98–1.1) | 0.16 |
| Mid circumferential | 0.87 (0.74–1) | 0.084 |
| Mid longitudinal | 1 (0.88–1.2) | 0.62 |
| Apical radial | 1 (0.98–1) | 0.43 |
| Apical circumferential | 0.94 (0.85–1) | 0.2 |
| Apical longitudinal | 1.1 (0.97–1.3) | 0.12 |
| Global radial | 1 (0.98–1.1) | 0.22 |
| Global circumferential | 0.93 (0.81–1.1) | 0.26 |
| Global longitudinal | 1.1 (0.88–1.3) | 0.5 |
| LGE pericardial enhancement | 1.5 (0.44–4.9) | 0.53 |
| LGE grading | 1.5 (0.88–2.5) | 0.14 |
| T2 STIR | 2 (0.85–4.9) | 0.11 |
| T1 mapping | 1 (1–1) | 0.61 |
BSA, body surface area; CRP, C-reactive protein; EDV, end-diastolic volume; ESV, end-systolic volume; LGE, late gadolinium enhancement; LV, left ventricle; STIR, short tau inversion recovery; SV, stroke volume; RV, right ventricle